A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

Pfizer (PFE) stock falls as the company posts mid-stage trial data for obesity therapy PF’3944. Read more here.

New weight loss drug by Pfizer shows promising results in trial - Pfizer acquired the drug’s developer following a bidding ...

Pfizer signaled some promise in its long-running attempt to develop an anti-obesity drug on Tuesday, but analysts say limited results and missing safety information left Wall Street still uncertain ...

Pfizer acquired the candidate following a bidding war with obesity giant Novo Nordisk for Metsera.

Danuglipron, a weight-loss pill, won’t continue its stages of testing after a person in a clinical trial was reportedly injured. Pfizer plans to explore other obesity treatments for testing. Pfizer is ...

Pfizer's latest trial data on a new obesity drug raises questions about its tolerability, leading to a slight drop in the ...

Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up ...